Eloxx Pharmaceuticals, Inc. has announced the pricing of a $66 million public offering alongside the planned uplisting of its common stock to the Nasdaq Capital Market. The clinical-stage biopharmaceutical company said its shares are expected to begin trading on Nasdaq under the ticker symbol “ELOX” on June 9, 2026. The transaction marks a significant capital markets development for the company as it seeks broader visibility among institutional and public-market investors.
Offering Details
The public offering consists of 2,975,000 shares of common stock priced at $11.00 per share, according to the company’s announcement. Eloxx is also offering pre-funded warrants to purchase up to 3,025,000 shares of common stock at $10.99 per warrant, reflecting the common stock offering price minus the $0.01 per-share exercise price. All securities in the offering are being sold by Eloxx, with gross proceeds expected to total approximately $66.0 million before underwriting discounts, commissions, and other expenses.
Nasdaq Uplisting
The company’s move to the Nasdaq Capital Market is expected to provide a more prominent trading venue for its shares. Eloxx said the common stock is scheduled to begin trading on Nasdaq on June 9, 2026, while the offering is expected to close on June 10, 2026, subject to customary closing conditions. The uplisting is notable for a company operating in the biotechnology sector, where access to capital and investor visibility can play an important role in supporting research and development plans.
Company and Pipeline Context
Eloxx Pharmaceuticals is developing small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. This approach is intended to support production of full-length proteins, a key objective in diseases where genetic mutations interfere with normal protein synthesis. As a clinical-stage company, Eloxx remains focused on advancing its platform and pipeline while navigating the financing needs common to drug developers before commercial revenue generation.
Transaction Participants
Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner, adding sector-focused capital markets support to the transaction. The company said a registration statement on Form S-1 tied to the offering was filed with the U.S. Securities and Exchange Commission and became effective on June 8, 2026.
Market and Regulatory Considerations
The offering is being conducted through a prospectus, and Eloxx emphasized that the announcement does not constitute an offer to sell or a solicitation to buy securities in jurisdictions where such activity would be unlawful. The company also noted that statements about expected proceeds, trading timing, and closing are forward-looking and subject to market conditions and other risks. For investors, the transaction combines potential balance-sheet strengthening with the dilution and execution risks typically associated with public equity offerings.
Eloxx Pharmaceuticals’ $66 million offering and Nasdaq uplisting represent an important step in the company’s public-market strategy. By raising capital and moving to a national exchange, the company is positioning itself for greater market exposure as it continues developing therapies aimed at diseases involving nonsense mutations. The next key milestones are the start of Nasdaq trading under “ELOX” and the expected closing of the offering, both of which remain subject to the conditions outlined by the company.